Depletion of FAP-expressing stromal cells resulted in a better immunological response and a lower tumor burden [29, 35],These findings may suggest therapeutics that selectively target FAP-expressing cells, but not other cancer-associated stromal cells, may result in a better prognosis. The gene discussed is FAP; the disease is neoplasm.